SXTP stock icon

60 Degrees Pharmaceuticals
SXTP

$0.23
1.71%

Market Cap: 2.86M

 

About: 60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

Employees: 2

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

100% more funds holding

Funds holding: 4 [Q4 2023] → 8 (+4) [Q1 2024]

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

3.59% less ownership

Funds ownership: 7.98% [Q4 2023] → 4.38% (-3.59%) [Q1 2024]

73% less capital invested

Capital invested by funds: $467K [Q4 2023] → $127K (-$341K) [Q1 2024]

Research analyst outlook

We haven’t received any recent analyst ratings for SXTP.

Financial journalist opinion

Neutral
GlobeNewsWire
1 month ago
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in humans The study will be the world's first clinical trial to evaluate tafenoquine in human babesiosis patients Enrollment will begin after a site initiation visit in Boston on June 13, 2024 Agreements are being negotiated with two other prominent university hospitals to expand recruitment in the Northeast U.S. where the incidence of babesiosis has been increasing; babesiosis, a tick-borne and potentially life-threatening illness, is an orphan disease Case studies in the medical literature suggest that tafenoquine may be a promising alternative for the treatment of some patients hospitalized with relapsing babesiosis WASHINGTON, May 30, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has entered into an agreement with Tufts Medical Center in Boston to conduct the world's first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients. Recruitment of at least 24 hospitalized patients diagnosed with babesiosis will begin after a site initiation visit at Tufts Medical Center on June 13, 2024.
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind